Looking into this for someone else

Someone you care about is unwell, and you want to be useful. You can look through what’s recruiting in Canada, keep what seems worth a second look, and send it to them or their doctor in one message.

Whether they follow any of it up is theirs to decide.

A Care Package is a note you put together

As you look, keep the trials that seem worth a second look. When you’re ready, they go to the person you’re thinking of — or to their doctor — as one plain-language note, in your words. Nothing is sent until you say so.

  1. LookBrowse what’s recruiting in Canada.
  2. KeepSave the ones worth a second look.
  3. SendOne note, in your words, when you’re ready.

Whether they read it, or do anything with it, is entirely theirs. You don’t need their details to do any of this.

Not sure how to bring it up? A few things worth knowing first →

RecruitingDrugDeviceBehavioralOlder adultsHealthy volunteers
Breast Cancer →

84 trials matching “Breast Cancer” · showing 30

Comparing Ovarian Function Suppression + with Adjuvant Chemotherapy + Ovarian for breast cancer

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Ovarian Function Suppression + Aromatase Inhibitor. Group B, the comparison group, receives Adjuvant Chemotherapy + Ovarian Function Suppression and Ovarian Function Suppression + Aromatase Inhibitor.

Sites in Montreal, Barrie and 9 more cities

  • Phase 3
  • 2 groups
  • Sites in Barrie, Kitchener and 9 more cities
  • Recruiting

Official title: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Breast Cancer · NRG Oncology

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches.

Comparing 4 approaches for advanced breast cancer

Explore this study →

There are 4 groups in this study. Group A receives Saruparib (AZD5305) and Camizestrant. Group B, the comparison group, receives one or more of: Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole and Exemestane. Group C receives Camizestrant, together with one or more of: Abemaciclib, Ribociclib and Palbociclib. …and 1 more groups.

Sites in Montreal, Toronto and 2 more cities

  • Phase 3
  • 4 groups
  • Sites in Toronto, Greenfield Park and 2 more cities
  • Recruiting

Official title: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Advanced Breast Cancer · AstraZeneca

Comparing 4 approaches for breast neoplasms

Explore this study →

There are 4 groups in this study. Group A receives Patritumab deruxtecan and Trastuzumab, together with one or more of: Trastuzumab Biosimilar. Groups B and D receive Patritumab deruxtecan, Pertuzumab and Trastuzumab, together with one or more of: Trastuzumab Biosimilar. Group C receives Patritumab deruxtecan, Trastuzumab and Tucatinib, together with one or more of: Trastuzumab Biosimilar.

Sites in Montreal, Kingston and 1 more city

  • Phase 1
  • 4 groups
  • Sites in Kingston, Toronto and 1 more city
  • Recruiting

Official title: Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Breast Neoplasms · Merck Sharp & Dohme LLC

Comparing 3 approaches for metastatic breast cancer

Explore this study →

There are 3 groups in this study. Group A receives Phesgo and Taxane-based Chemotherapy. Group B receives Inavolisib and Phesgo, together with one or more of: Optional Endocrine Therapy of Investigator's Choice. Group C, the comparison group, receives Placebo and Phesgo, together with one or more of: Optional Endocrine Therapy of Investigator's Choice.

Sites in Montreal, Calgary and 5 more cities

  • Phase 3
  • 3 groups
  • Sites in Calgary, Moncton and 5 more cities
  • Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer · Hoffmann-La Roche

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Concord provides information only. Trial listings come from public registries, and whether anyone can take part is decided by the trial site and their own care team.